References
Kalow W (1982) Ethnic differences in drug metabolism. Clin Pharmacokinet 7: 373–400
Bertilsson L, Mellstrom B, Sawe J, Sjoqvist F (1981) Pharmacogenetic aspects of the metabolism of tricyclic antidepressants. In: Langer SZ, Takahashi R, Segawa T, Briley M (ed) New vistas in depression. Pergamon, Oxford
Kupfer A, Preisig R (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26: 753–759
Alvan G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39: 533–537
Islam SI, Idle JR, Smith RL (1980) The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population. Xenobiotica 10: 819–825
Mahgoub A, Idle JR, Smith RL (1979) A population and family study of the defective alicyclic hydroxylation of debrisoquine among Egyptians. Xenobiotica 9: 51–56
Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Inter-ethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38: 402–408
Lee EJD, Yeoh PN, Gong NH (1988) Oxidation phenotyping in Chinese and Malay populations. Clin Exp Pharmacol Physiol 15: 889–891
Lou YC, Ying L, Bertilsson L, Sjoqvist F (1987) Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet II: 852–853
Wanwimolruk S, Patamasucon P, Lee EJD (1990) Evidence for the polymorphic oxidation of debrisoquine in the Thai population. Br J Clin Pharmacol 29: 244–247
Peart GF, Boutagy J, Shenfield GM (1986) Debrisoquine oxidation in an Australian population. Br J Clin Pharmacol 21: 465–471
Wanwimolruk S, Ferry DG (1990) Rapid high-performance liquid chromatographic method for the analysis of debrisoquine and 4-hydroxydebrisoquine in urine without derivatization. J Liq Chromatogr 13: 961–968
Price-Evans DA, Mahgoub A, Sloan TP, Idle JR (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105
Brosen K, Otton SV, Gram LF (1985) Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol 57: 357–360
Szorady I, Santa A (1987) Drug hydroxylator phenotype in Hungary. Eur J Clin Pharmacol 32: 325
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wanwimolruk, S., Denton, J.R., Ferry, D.G. et al. Polymorphism of debrisoquine oxidation in New Zealand Caucasians. Eur J Clin Pharmacol 42, 349–350 (1992). https://doi.org/10.1007/BF00266364
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00266364